Clinical Trials Logo

Clinical Trial Summary

This is a double-blind, randomized, placebo-controlled, crossover trial, to test the hypothesis that RDD1609 is effective in treating idiopathic pruritus ani.


Clinical Trial Description

This is a phase 2a randomized double-blinded placebo-controlled cross-over design study in patients with idiopathic pruritus ani. 24 patients, male and females, aged 18 -65 with severe idiopathic pruritus ani (VAS score above 60), will be randomized to this study. Patients that meet all inclusion criteria and do not have exclusion criteria at randomization visit will be randomly assigned to one of the two treatment groups: Group 1 will receive 3 weeks of RDD1609 for 3 weeks, followed by 3 weeks of treatment with placebo. Group 2 will receive 3 weeks of treatment with placebo followed by 3 weeks of treatment with RDD1609. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03757403
Study type Interventional
Source RDD Pharma Ltd
Contact
Status Withdrawn
Phase Phase 2
Start date May 1, 2020
Completion date December 31, 2020